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Background. We recently described a genomic pathway approach to study complex diseases. We demonstrated that models
constructed using single nucleotide polymorphisms (SNPs) within axon guidance pathway genes were highly predictive of
Parkinson disease (PD) susceptibility, survival free of PD, and age at onset of PD within two independent whole-genome
association datasets. We also demonstrated that several axon guidance pathway genes represented by SNPs within our final
models were differentially expressed in PD. Methodology/Principal Findings. Here we employed our genomic pathway
approach to analyze data from a whole-genome association dataset of amyotrophic lateral sclerosis (ALS); and demonstrated
that models constructed using SNPs within axon guidance pathway genes were highly predictive of ALS susceptibility (odds
ratio=1739.73, p=2.92610
260), survival free of ALS (hazards ratio=149.80, p=1.25610
274), and age at onset of ALS (R
2=0.86,
p=5.96610
266). We also extended our analyses of a whole-genome association dataset of PD, which shared 320,202 genomic
SNPs in common with the whole-genome association dataset of ALS. We compared for ALS and PD the genes represented by
SNPs in the final models for susceptibility, survival free of disease, and age at onset of disease and noted that 52.2%, 37.8%,
and 34.9% of the genes were shared respectively. Conclusions/Significance. Our findings for the axon guidance pathway
and ALS have prior biological plausibility, overlap partially with PD, and may provide important insight into the causes of these
and related neurodegenerative disorders.
Citation: Lesnick TG, Sorenson EJ, Ahlskog JE, Henley JR, Shehadeh L, et al (2008) Beyond Parkinson Disease: Amyotrophic Lateral Sclerosis and the
Axon Guidance Pathway. PLoS ONE 3(1): e1449. doi:10.1371/journal.pone.0001449
INTRODUCTION
We recently described a genomic pathway approach as a method
to predict complex diseases, and demonstrated that models of
single nucleotide polymorphisms (SNPs) within axon guidance
pathway genes were highly predictive of Parkinson disease (PD)
susceptibility, survival free of PD, and age at onset of PD [1]. Our
findings suggested that mechanisms such as a neurodevelopmental
defect in brain wiring, or lifelong defects in axonal maintenance
and repair, could contribute to the pathogenesis of PD.
Amyotrophic lateral sclerosis (ALS) is also a complex, aging
related disease of the nervous system affecting motor control. Both
ALS and PDare characterized by degeneration ofneuronswith long
axonal projections. Indeed, for ALS, the neurons that degenerate
have some of the longest projections within the nervous system,
extending from near the surface of the brain through the length of
the spinal cord; or from the spinal cord segments to the muscles of
the distal extremities. As for PD, it is plausible that a defect in axonal
guidance or maintenance or repair could predispose to ALS [2].
Indeed, prior evidence suggests that axon guidance factors may
contribute to the pathogenesis of ALS. Gene ontology pathways
relating to axonal function are differentially expressed in ALS,
including pathways that relate to the cytoskeleton (processes
including axonal outgrowth and transport) and to neuronal
maintenance and signaling (processes including axonal differenti-
ation, plasticity, maintenance, and repair) [3]. Furthermore,
studies in experimental models and in patients have implicated
specific axon guidance pathway genes, or their transcripts or
proteins, in the pathogenesis of ALS. These include the genes
CDC42 (GeneID 998), CDK5 (GeneID 1020), CXCL12 (GeneID
6387), CXCR4 (GeneID 7852), EPHB2 (GeneID 2048), L1CAM
(GeneID 3897), MET (GeneID 4233), PAK1 (GeneID 5058), PAK3
(GeneID 5063), RAC1 (GeneID 5879), RHOA (GeneID 387), and
SEMA3A (GeneID 10371) [4–18]. Here and throughout the
publication, gene names and accession numbers (GeneIDs) were
assigned using the Entrez Gene website http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?db=gene.
In light of this prior biological plausibility, we postulated that
models constructed using SNPs within axon guidance pathway
genes might predict ALS outcomes as they had predicted PD
outcomes; and that the final predictive models for ALS and PD
might include SNPs within some of the same axon guidance
pathway genes. To test these hypotheses, we analyzed two whole-
genome association datasets, one for ALS and one for PD [19,20].
We chose to compare the datasets for these two studies specifically
because the samples were selected from the same biospecimens
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same unrelated controls); because the sample sizes employed by
the two studies were similar (,270 cases and ,270 unrelated
controls each); and because the same laboratory genotyped the
samples using the same platform and overlapping SNP arrays.
MATERIALS AND METHODS
Bioinformatic Methods
To formally test our hypothesis, we consulted the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [21–23]. The
KEGG PATHWAY database is a bioinformatics resource that
provides wiring diagrams of molecular interactions, reactions, and
relations. There are at least 270 pathways in KEGG related to
Homo sapiens and diseases. This includes a detailed summary of the
axon guidance pathway, updated as recently as October 3, 2005
(http://www.genome.jp/dbget-bin/www_bget?path:hsa04360).
We identified all of the genes that encoded proteins within the
KEGG axon guidance pathway via Entrez Gene (http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db=Gene) and consulted the
UniGene database (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=unigene) to determine which of the genes were expressed
in the human brain (n=128). We then mined available whole-
genome association datasets for ALS and PD to identify those
SNPs that were genotyped in brain-expressed, axon-guidance
pathway genes as part of those studies [19,20]. Specifically, in
those studies, 555,352 unique SNPs were used from the Illumina
Infinium II HumanHap550 SNP assay for ALS and more than
408,000 unique SNPs were used from the Illumina Infinium I and
HumanHap300 assays for PD. Details regarding the sampling
methods for the ALS and PD datasets have been previously
reported [19,20]. In brief, samples were obtained from the Coriell
Institute for Medical Research, NJ, USA. Cases fulfilled pre-
specified diagnostic criteria for ALS or PD, and controls were
neurologically normal (no history of ALS or PD or other
neurological disorders). The case and control subjects were of
the same ethnic origin, but were not matched for age or sex.
Statistical Methods (ALS)
All statistical tests were two-tailed, and considered significant at
the conventional alpha level of 0.05. All statistical analyses were
performed in SAS v. 9.1 (SAS Institute Inc., Cary, NC) or S-Plus
v. 7 (Insightful Corp., Seattle, WA). We considered three outcomes
of interest: 1) ALS susceptibility, 2) survival free of ALS, and 3) age
at onset of ALS. We sought to identify joint action models of SNPs
from the axon guidance pathway that predicted each of the three
outcomes.
For thefirst outcome, we used unconditionallogisticregressions to
examine associations of the SNPs with ALS susceptibility while
adjusting for age and gender [24]. For eachSNP, we calculated odds
ratios(ORs),95%confidenceintervals(CIs),andpvalues.Goodness-
of-fit was assessed through measuring concordance and visually
through histograms of predicted probabilities [25]. We estimated
overall ORs by categorizing the predicted probability of ALS from
the model into four groups (,0.25, 0.25–0.50, 0.50–0.75, and
.0.75), and then calculating the ORs for each group relative to the
,0.25 group.Weusedalikelihood ratiotesttoassessthe significance
of the overall model, and calculated a 95% bias-corrected bootstrap
CI for the associated p value using 10,000 re-samples.
For the second outcome, we used Cox proportional hazards
models to test for associations of the SNPs with survival free of ALS
[26]. For each SNP, we calculated hazards ratios (HRs), 95% CI,
and p values. Concordance was again calculated for the proportional
hazards models, and Kaplan-Meier plots of categorized scores
predicting risk of ALS were generated to provide visual gauges for
goodness-of-fit [27]. We also calculated HRs for risk groups
categorized at the quartiles, using the lowest risk group as reference.
We used a likelihood ratio test to assess the significance of the overall
model, and calculated a 95% bias-corrected bootstrap CI for the
associated p value using 10,000 re-samples.
For the third outcome, we predicted the reported age at onset of
ALS using multiple regression models [28]. Goodness-of-fit was
described through the model R
2 values and plots of the predicted vs.
observed ages at onset. We used an F test to assess the significance of
the overall model, and calculated a 95% bias-corrected bootstrap CI
for the associated p value and the R
2 using 10,000 re-samples.
Assumptions were tested throughout. We performed tests of linkage
disequilibrium in unrelated controls for the SNPs in the final models
for the three outcomes using LDSELECT v. 1.0 (copyright 2004 by
Deborah A. Nickerson, Mark Rieder, Chris Carlson, Qian Yi,
University of Washington) with a threshold R
2 of 0.80.
Figure S1 summarizes the scheme used to develop models for
each outcome. Since the modes of expression of the alleles in the
SNPs of interest were not known, we first looked at each SNP
using three coding schemes: log-additive, Mendelian dominant,
and Mendelian recessive (Step 1). We simplified subsequent
analyses by removing from further consideration those SNPs with
no significant main effects in any coding scheme (Step 2).
Removing those SNPs was a conservative approach, potentially
biasing our tests towards the null hypotheses, since the SNPs were
prevented from possibly entering the joint action models after
adjustment for other variables. We generally coded the remaining
SNPs using the schemes which produced the smallest p values,
since these provided our best estimates of the modes of expression
in our data (Step 3). For each outcome, we then created multiple
sets of SNPs, where each set contained only SNPs with at least a
certain number of non-missing values (Step 4). This was done to
address issues due to missing values.
While most SNPs had fairly complete data, others had missing
values from substantial (up to 28%) numbers of subjects. We
therefore chose an approach where we constructed candidate
models using sets of SNPs with fairly complete data (effective
sample sizes close to the maximum) to explain as much of the
outcomes as possible, then checked to see if adding other SNPs on
top of the candidate models would contribute significantly. We
constructed the candidate models for each set using standard
automated procedures (Step 5), and selected a final candidate
model for each outcome based on significance and goodness-of-fit
(Step 6). We then added other SNPs, which were significant given
the candidate models (Step 7), and significant pair-wise interac-
tions (Step 8).
Statistical Methods (PD)
Our statistical methods for PD were identical to those for ALS. We
considered three outcomes of interest: 1) PD susceptibility, 2)
survival free of PD, and 3) age at onset of PD. We sought to
identify joint action models of SNPs from the axon guidance
pathway that predicted each of the three outcomes. The methods
employed to study the association of SNPs with each outcome and
the scheme used to develop predictive models for each outcome
are described above.
RESULTS
Results (ALS)
The primary whole-genome association study dataset employed by
this study included 275 ALS cases and 269 unrelated controls. The
median age at onset of ALS among the cases was 54 years (range
Axon Guidance, ALS, and PD
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previously reported [19]. Our bioinformatic methods identified
128 brain-expressed axon guidance pathway genes and our SNP
dataset included 4,133 SNPs within 124 of those genes.
ALS Susceptibility Of the 4,133 SNPs within brain-
expressed genes of the axon-guidance pathway, 442 SNPs
(10.7%) were individually associated with susceptibility to ALS,
as detailed in Text S1. Table S1A contains results for the final
model produced by running SNPs through the multi-stage process
to predict ALS susceptibility. This model used data from 542
unmatched ALS patients and unrelated controls (2 subjects were
missing data on one or more SNPs). The ORs (95% CIs) for the
groups defined by predicted ALS probability of ,0.25, 0.25–0.50,
0.50–0.75, and .0.75 were as follows: 1 (reference), 17.60 (5.70–
54.36), 112.00 (35.45–353.83), and 1739.73 (523.53–5781.32)
respectively. Since we were interested in the significance of the
pathway, rather than individual SNPs, the p value for the overall
model was of primary importance. In this case, the model had an
overall p value of 2.92610
260 (95% CI 8.34610
252-1.16610
268).
This model significantly predicted whether an individual was a
case or an unrelated control. The predicted probabilities of ALS
were very high (towards 1) for most of the cases, and very low
(towards 0) for most of the unrelated controls (Figure 1A). Indeed
78% of the cases had predicted probabilities above 0.9, and 77%
of unrelated controls had predicted probabilities below 0.1. As
shown by Figure 1A, the model did not completely distinguish the
two groups; some ALS cases had low predicted probabilities, and
some controls had high predicted probabilities. However, the
concordance for the model was about 0.99, indicating excellent
agreement between predicted and observed case/control status.
Survival Free of ALS Of the 4,133 SNPs, 451 (10.9%) were
individually associated with survival free of ALS (hazard function)
using Cox proportional hazards models, as detailed in Text S1.
Table S1B contains results for the final proportional hazards
model produced by running SNPs through the multi-stage process
to predict survival free of ALS. This model used data from 274
ALS patients (1 patient was missing data on one or more SNPs). In
this case, the model had an overall p value of 1.25610
274 (95% CI
2.22610
260-1.24610
289). By contrast, the model was not
significant at predicting survival (age at study) in the unrelated
controls (p=0.15). This last finding suggests that the model
predicts survival free of ALS (hazard function), but not survival in
general, and that the model is specific for ALS cases.
Figure 1B shows a Kaplan-Meier plot to describe the results of
the model. The groups were formed by calculating a risk score for
each ALS patient using the equation from the proportional
hazards model, then categorizing the score at the 25
th (Q1), 50
th
(Q2), and 75
th (Q3) percentiles. The survival curves separated
nicely right from the earliest ages of onset. By age 50, only 9% of
ALS patients in the predicted highest risk group were still free of
ALS, whereas 96% of ALS patients in the predicted lowest risk
group were free of ALS. By age 55, none of the ALS patients in the
predicted highest risk group were still free of ALS, whereas 93% of
ALS patients in the predicted lowest risk group were free of ALS.
The median ages at onset for each group, from lowest risk group to
highest risk group, were 71, 59, 52, and 43, a difference in survival
Figure 1. Final Models Predicting ALS Outcomes. Figure 1A (left). Goodness-of-Fit of Final Model Using Axon Guidance Genes to Predict
Susceptibility to ALS. Histogram of predicted probabilities of ALS in cases (a). Histogram of predicted probabilities of ALS in controls (b). A perfect fit
would have all predicted probabilities for cases equal to one, and all predicted probabilities for controls equal to zero. A model with no explanatory
value would have histograms that were indistinguishable from each other. Figure 1B (center). Kaplan-Meier Survival Plot for Age at Onset in ALS
Patients, Grouped by Categorized Risk Score from Proportional Hazards Model. The model clearly differentiates between early age at onset cases and
late age at onset cases. Cases generating the long-dashed line were predicted to be at highest risk for early onset of ALS, followed by the medium-
dashed, short-dashed, and continuous lines respectively. Since only cases were included, all of the lines end at zero percent free of ALS. Figure 1C
(right). Predicted vs. Reported Age at Onset in ALS Patients. Points indicate reported individual values, and the line represents perfect agreement.I n
this case, the pattern shows a fairly tight elliptical pattern, reflecting a good fit and high R
2 of 0.86. The fit appears equally good from the minimum to
maximum reported age at onset.
doi:10.1371/journal.pone.0001449.g001
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for this model was 0.86. The HRs (95% CIs) for the four groups,
from lowest to highest risk, were 1 (reference), 7.35 (4.50–12.00),
37.29 (20.49–67.87), and 149.80 (77.21–290.63).
Age at Onset of ALS Of the 4,133 SNPs, 487 (11.8%) were
individually associated with age at onset of ALS using linear
regression models, as detailed in Text S1. Table S1C contains
results for the final model produced by running SNPs through the
multi-stage process to predict age at onset of ALS. This model
used data from 272 ALS patients (3 patients were missing data on
one or more SNPs). In this case, the model had an overall p value
of 5.96610
266 (95% CI 4.95610
251-8.42610
280). By contrast,
the set of SNPs was not significant at predicting age at study of the
unrelated controls (p=0.55). This last finding suggests that the
model predicts age at onset of ALS, not age at the time of the
study, and that the model is specific for ALS cases.
Figure 1C shows a plot of predicted age at onset vs. reported age
at onset to summarize the results of the model. The data are
distributed in an elliptical pattern, reflecting the model R
2 of 0.86
(95% CI 0.83–0.88). The model explained about 86% of the
variability in age at onset of ALS.
Other combinations of SNPs from the axon guidance pathway
also performed quite well in predicting ALS susceptibility, survival
free of ALS, and age at onset of ALS. Although the models
reported in this manuscript provided good fits to our data, our
results do not preclude other combinations of axon guidance
pathway SNPs as significant predictors of ALS. The SNPs in the
final models that we selected showed no significant linkage
disequilibrium in unrelated controls.
Results (PD)
The primary whole-genome association study dataset employed by
this study included 269 PD cases and 267 unrelated controls. The
median age at onset of PD among the cases was 64 years (range
13–84). Details regarding the SNP markers genotyped were
previously reported [20]. Our bioinformatic methods identified
128 brain-expressed axon guidance pathway genes and our SNP
dataset included 3,095 SNPs within 122 of those genes.
PD Susceptibility Of the 3,095 SNPs within brain-expressed
genes of the axon-guidance pathway, 295 SNPs (9.5%) were
individually associated with susceptibility to PD, as detailed in
Text S2. Table S2A contains results for the final model produced
by running SNPs through the multi-stage process to predict PD
susceptibility. This model used data from 516 unmatched PD
patients and unrelated controls (20 subjects were missing data on
one or more SNPs). The ORs (95% CIs) for the groups defined by
predicted PD probability of ,0.25, 0.25–0.50, 0.50–0.75, and
.0.75 were as follows: 1 (reference), 1.85 (0.58–5.92), 19.03 (8.56–
42.30), and 391.82 (157.94–972.06), respectively. Since we were
interested in the significance of the pathway, rather than
individual SNPs, the p value for the overall model was of
primary importance. In this case, the model had an overall p value
of 8.10610
271 (95% CI 2.34610
264-1.67610
276). This model
significantly predicted whether an individual was a case or an
unrelated control. The predicted probabilities of PD were very
high (towards 1) for most of the cases, and very low (towards 0) for
most of the unrelated controls (Figure 1A). Indeed 72% of the
cases had predicted probabilities above 0.9, and 69% of unrelated
controls had predicted probabilities below 0.1. As shown by
Figure 2A, the model did not completely distinguish the two
groups; some PD cases had low predicted probabilities, and some
controls had high-predicted probabilities. However, the
concordance for the model was about 0.98, indicating excellent
agreement between predicted and observed case/control status.
Survival Free of PD Of the 3,095 SNPs, 327 (10.6%) were
individually associated with survival free of PD (hazard function)
using Cox proportional hazards models, as detailed in Text S2.
Table S2B contains results for the final proportional hazards model
produced by running SNPs through the multi-stage process to
predict survival free of PD. This model used data from 264 PD
patients (4 patients were missing data on one or more SNPs, and one
patient with a questionable age at onset of 13 years was removed
from the analyses). In this case, the model had an overall p value of
9.02610
258 (95% CI 1.48610
246-7.90610
270). By contrast, the
model was not significant at predicting survival (age at study) of the
unrelatedcontrols(p=0.80).Thislastfinding suggeststhatthe model
predicts survival free of PD (hazard function), but not survival in
general, and that the model is specific for PD cases.
Figure 2B shows a Kaplan-Meier plot to describe the results of the
model. The groups were formed by calculating a risk score for each
PD patient using the equation from the proportional hazards model,
then categorizing the score at the 25
th (Q1), 50
th (Q2), and 75
th (Q3)
percentiles. The survival curves separated nicely right from the
earliest ages of onset. By age 60, only 21% of PD patients in the
predicted highestriskgroupwerestill free ofPD,whereas98%ofPD
patients in the predicted lowest risk group were free of PD. By age
70, none of the PD patients in the predicted highest risk group were
still free of PD, whereas 74% of PD patients in the predicted lowest
riskgroupwere freeofPD. The medianagesatonset for eachgroup,
from lowest risk group to highest risk group, were 75, 68, 63, and 58,
a difference in survival free of PD of 17 years from lowest to highest.
The concordance for this model was 0.85. The HRs (95% CIs) for
the four groups, from lowest to highest risk, were 1 (reference), 4.65
(3.05–7.08), 17.36 (10.54–28.57), and 72.90 (41.52–128.00).
Age at Onset of PD Of the 3,095 SNPs, 326 (10.5%) were
individuallyassociatedwithageatonsetofPDusinglinearregression
models, as detailed in Text S2. Table S2C contains results for the
final model produced by running SNPs through the multi-stage
processto predictage atonset of PD. This model used data from 261
PD patients (7 patients were missing data on one or more SNPs, and
one patient witha questionable ageatonset of13 yearswasremoved
from the analyses). In this case, the model had an overall p value of
4.52610
261 (95% CI 8.97610
246-2.97610
275). By contrast, the set
ofSNPswasnotsignificantat predictingage at studyofthe unrelated
controls (p=0.98). This last finding suggests that the model predicts
age at onset of PD, not age at the time of the study, and that the
model is specific for PD cases.
Figure 2C shows a plot of predicted age at onset vs. reported age
at onset to summarize the results of the model. The data are
distributed in an elliptical pattern, reflecting the model R
2 of 0.86
(95% CI 0.83–0.89). The model explained about 86% of the
variability in age at onset of PD.
Other combinations of SNPs from the axon guidance pathway
also performed quite well in predicting PD susceptibility, survival
free of PD, and age at onset of PD. Although the models reported
in this manuscript provided good fits to our data, our results do not
preclude other combinations of axon guidance pathway SNPs as
significant predictors of PD. The SNPs in the final models that we
selected showed no significant linkage disequilibrium in unrelated
controls.
Results (Comparison of Final Models for ALS and PD)
The final model predicting ALS susceptibility contained 31 genes,
and the final model predicting PD susceptibility contained 39
genes. The SNPs and genes included in the final models are listed
in the supporting information (Tables S1A and S2A). Combined,
the models for ALS and PD contained 46 genes, of which 24
(52.2%) were shared, and 22 (47.8%) were not. Of the 22 genes
Axon Guidance, ALS, and PD
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15 were in the PD model but not in the ALS model.
The final model predicting survival free of ALS contained 34
genes, and the final model predicting survival free of PD contained
28 genes. The SNPs and genes included in the final models are
listed in the supporting information (Tables S1B and S2B).
Combined, the models for ALS and PD contained 45 genes, of
which 17 (37.8%) were shared, and 28 (62.2%) were not. Of the 28
genes not shared, 17 were in the ALS model but not the PD
model, and 11 were in the PD model but not in the ALS model.
The final model predicting age at onset of ALS contained 30
genes, and the final model predicting age at onset of PD contained
28 genes. The SNPs and genes included in the final models are
listed in the supporting information (Tables S1C and S2C).
Combined, the models for ALS and PD contained 43 genes, of
which 15 (34.9%) were shared, and 28 (65.1%) were not. Of the 28
genes not shared, 15 were in the ALS model but not the PD
model, and 13 were in the PD model but not in the ALS model.
Figure 3 displays the distributions of the significant SNPs in the
genes from the ALS and PD final models (as listed in Tables S1A-
S2C). While the samples for the ALS and PD whole-genome
association studies were genotyped in the same laboratory using an
Illumina platform, the SNPs assayed overlapped only partially.
Specifically, 320,202 SNPs were common to both the ALS and PD
datasets, but 234,957 SNPs were unique to the ALS dataset and
88,599 SNPs were unique to the PD dataset. In other words, of the
SNPs present in the ALS dataset, only 57.6% were also present in
the PD dataset; and of the SNPs present in the PD dataset, only
78.3% were also present in the ALS dataset. We again note that
the final models were not exclusive; other combinations of SNPs
(and genes) also had predictive value for the three outcomes for
either ALS or PD (data not shown).
DISCUSSION
These results suggest that common gene variants in the axon
guidance pathway contribute to the pathogenesis of ALS as well as
PD. The axon guidance pathway includes several ligands,
receptors, and intermediary proteins that provide a complex and
dynamic set of cues that either repel or attract axons toward their
synaptic targets during brain and spinal cord development.
Moreover, the same pathway maintains and repairs axons and
their connections throughout life [29,30]. All major families of
axon guidance pathway ligands (ephrins, netrins, semaphorins,
slits), their receptors, and several intermediary proteins have been
reported to play a role in the axon guidance of motor neurons [31–
53]. Hence it is not surprising that our final models for ALS
susceptibility, survival free of ALS, and age at onset of ALS
included SNPs from many axon guidance pathway genes (see
Tables S1A-C). It is possible that motor neurons and dopamine
neurons are selectively vulnerable to neurodegenerative processes
in part because they have long and/or highly collateralized axons
as compared to less vulnerable neurons [54–56]. Hence, normal
axon guidance pathway function may be of importance to develop
and maintain nervous system health.
We observed only partial overlap of axon guidance pathway
gene signatures for ALS and PD outcomes. Conceivably, there are
sub-pathway patterns of difference in the gene signatures for the
Figure 2. Final Models Predicting PD Outcomes. Figure 2A (left). Goodness-of-Fit of Final Model Using Axon Guidance Genes to Predict
Susceptibility to PD. Histogram of predicted probabilities of PD in cases (a). Histogram of predicted probabilities of PD in controls (b). A perfect fit
would have all predicted probabilities for cases equal to one, and all predicted probabilities for controls equal to zero. A model with no explanatory
value would have histograms that were indistinguishable from each other. Figure 2B (center). Kaplan-Meier Survival Plot for Age at Onset in PD
Patients, Grouped by Categorized Risk Score from Proportional Hazards Model. The model clearly differentiates between early age at onset cases and
late age at onset cases. Cases generating the long-dashed line were predicted to be at highest risk for early onset of PD, followed by the medium-
dashed, short-dashed, and continuous lines respectively. Since only cases were included, all of the lines end at zero percent free of PD. Figure 2C
(right). Predicted vs. Reported Age at Onset in PD Patients. Points indicate reported individual values, and the line represents perfect agreement. In
this case, the pattern shows a fairly tight elliptical pattern, reflecting a good fit and high R
2 of 0.86. The fit appears equally good from the minimum to
maximum reported age at onset.
doi:10.1371/journal.pone.0001449.g002
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semaphorin or slit families of ligands and receptors; genes
encoding ligands versus receptors or intermediary proteins; genes
encoding proteins that are primarily chemoattractant versus
chemorepellant; etc.). However, we did not recognize any definite
patterns of difference in the gene signatures for ALS and PD. Such
patterns may become apparent by comparing ALS and PD
predictive SNP models across multiple datasets. While there are
two other whole-genome association studies of ALS published to
date, they are not suitable for our genomic pathway analyses that
require individual level genotyping data. Specifically, the one
study performed pooled genotyping of cases and controls [57].
The other study performed individual-level genotyping, but at this
time only summary data are available (the approved protocols did
not permit public release of individual genotyping data) [58].
We also note that while the gene signatures for ALS and PD are
partially overlapping, that the genes associated with these two
diseases may have been highlighted by different SNPs and with
different directions of effect (ORs, HRs, or R
2 values greater or less
than 1). Unfortunately, the functional effects of most of the SNPs
included in either whole-genome association study (or the disease
alleles that they map) are unknown [19,20], and it is unknown
whether the genes that were mapped by the SNPs in the final
models are expressed specifically by the vulnerable cell types in
Figure 3. Distributions of the Significant SNPs in the Genes from the ALS and PD Final Models. This figure shows results from our final models for
susceptibility (a), survival free of disease (b), and age at onset of disease (c). Blue bars represent ALS, and red bars, PD.
doi:10.1371/journal.pone.0001449.g003
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Furthermore, we note that while the axon guidance pathway SNPs
genotyped in the ALS and PD datasets were partially overlapping,
that there were many SNPs unique to either dataset. Some linkage
disequilibrium bins within axon guidance pathway genes may not
have been mapped by the SNPs included on the genotyping
arrays.
Our final SNP models for ALS and PD had high model
concordance and R
2 values, and the sensitivity and specificity of
the susceptibility model for ALS were 94% and 94%, and for PD
were 92% and 92%. The p values for the three outcomes for ALS
and PD were robust, as demonstrated by their 95% CIs (internal
validity of the findings). It would be tempting to consider the
development for clinical practice of predictive multiplex SNP
assays based on our final models. However, we caution that our
models were constructed using data from individual SNPs, which
typically have small effect sizes. With as few as 269 cases and 267
controls, we could detect odds ratios as small as 1.8 in SNPs with
allele frequencies of 0.10 or higher (alpha=0.05, beta=0.10).
While 80% of SNPs in the ALS dataset and 86% of SNPs in the
PD dataset had allele frequencies of 0.10 or higher, the available
sample size limits our ability to detect significant main effects of
individual SNPs. However, for our joint effects SNP models we
had ample power, as fewer than 100 subjects total were required to
detect the observed effect sizes. The small available sample size
biased our results conservatively to the null hypothesis. With larger
sample sizes, additional SNPs with lower allele frequencies and
smaller main effects may be included in the final models.
Furthermore, individual SNPs may have variable frequencies
and carry different linkage disequilibrium information content
across populations. Some disease gene loci may be population
specific. We note that for each of the three outcomes for ALS and
PD, multiple models of SNPs were predictive (we only illustrated
the models that provided the best fit to the available data). Efforts
to replicate our findings for ALS or PD might therefore consider
genotyping at least all of the SNPs that were in axon guidance
pathway genes in the featured whole-genome association datasets
[20,59], as listed in Text S1 and S2, and might also consider
genotyping additional SNPs within the axon guidance pathway
(e.g., at least one SNP per linkage disequilibrium bin; for 6,014
bins and an r
2$0.9, about 8,200 tag SNPs in Caucasian samples).
The replication standard might be based upon the final model
concordance and p values for a given pathway and outcome,
rather than upon the findings for a pre-specified list of SNPs.
Our findings for axon guidance and ALS or PD do not preclude
the role of other genomic pathways in the etiology of these
disorders. However, the high model concordance and R
2 values
that we observed would suggest that within the available samples,
axon guidance pathway gene variability played a major role.
Indeed, a large-scale pathways-based association study in ALS
recently failed to exhibit significant findings for other candidate
pathways [60]. Our findings also do not preclude the role of
environmental factors in the etiology of these disorders [61].
However, we would encourage epidemiological and toxicological
studies of ALS and PD to also consider neurodevelopmental
mechanisms. Indeed, beta-N-methylamino alanine has been
proposed to be the exogenous toxin cause of Guamanian ALS
and Parkinsonism [62], and the toxin has a biphasic dose effect on
neuritic outgrowth in vitro [63].
Until now, genetic studies of complex diseases such as ALS and
PD have largely considered the main effects of SNPs, which are
small and of limited attributable risk [19,20,64,65]. By contrast,
our genomic pathway approach suggests that even for disorders
that appear sporadic, genetic factors may still play a major role.
SUPPORTING INFORMATION
Figure S1 Summary of the Scheme Used to Develop Models for
Each Outcome. The procedure employed to build joint action
models using SNPs from genes in the axon guidance pathway that
predict ALS or PD susceptibility, survival free of ALS or PD, and
age at onset of ALS or PD, within both whole-genome association
datasets [19,20], is presented.
Found at: doi:10.1371/journal.pone.0001449.s001 (3.45 MB TIF)
Text S1 Detailed SNP Identifier Information and Additional
Results for Three Outcomes (ALS). For each of the 4,133 axon
guidance pathway SNPs included in the ALS whole-genome
association dataset [19], provided are detailed SNP identifier
information and additional results for three outcomes: ALS
susceptibility, survivalfree ofALS, and predicted age at onset of ALS.
Found at: doi:10.1371/journal.pone.0001449.s002 (1.36 MB
TXT)
Text S2 Detailed SNP Identifier Information and Additional
Results for Three Outcomes (PD). For each of the 3,095 axon
guidance pathway SNPs included in the PD whole-genome
association dataset [20], provided are detailed SNP identifier
information and additional results for three outcomes: PD
susceptibility, survival free of PD, and predicted age at onset of PD.
Found at: doi:10.1371/journal.pone.0001449.s003 (1.02 MB
TXT)
Table S1 Table S1A. SNPs in Axon Guidance Pathway Genes
Predicting ALS Susceptibility. Data presented are within a whole-
genome dataset [19]. The results for the final SNP model are
presented. Other SNP models were also significant (data not shown).
Table S1B. SNPs in Axon Guidance Pathway Genes Predicting
Survival Free of ALS. Data presented are within a whole-genome
association dataset [19]. The results for the final SNP model are
presented. Other SNP models were also significant (data not shown).
Table S1C. SNPs in Axon Guidance Pathway Genes Predicting Age
at Onset of ALS. Data presented are within a whole-genome
association dataset [19]. The results for the final SNP model are
presented. Other SNP models were also significant (data not shown).
Found at: doi:10.1371/journal.pone.0001449.s004 (0.28 MB
DOC)
Table S2 Table S2A. SNPs in Axon Guidance Pathway Genes
Predicting PD Susceptibility. Data presented are within a whole-
genome association dataset [20]. The results for the final SNP
model are presented. Other SNP models were also significant (data
not shown). Table S2B. SNPs in Axon Guidance Pathway Genes
Predicting Survival Free of PD. Data presented are within a
whole-genome association dataset [20]. The results for the final
SNP model are presented. Other SNP models were also significant
(data not shown). Table S2C. SNPs in Axon Guidance Pathway
Genes Predicting Age at Onset of PD. Data presented are within a
whole-genome association dataset [20]. The results for the final
SNP model are presented. Other SNP models were also significant
(data not shown).
Found at: doi:10.1371/journal.pone.0001449.s005 (0.24 MB
DOC)
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